Prudential Financial Inc. lowered its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 42.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 254,168 shares of the company's stock after selling 190,286 shares during the quarter. Prudential Financial Inc. owned about 0.55% of Pacira BioSciences worth $4,789,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Caitlin John LLC boosted its position in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its stake in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares in the last quarter. Virtus Investment Advisers Inc. purchased a new position in shares of Pacira BioSciences during the third quarter worth $98,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after buying an additional 918 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on PCRX shares. Barclays raised their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright raised their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC boosted their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $27.22.
View Our Latest Research Report on PCRX
Pacira BioSciences Stock Down 4.9 %
Shares of PCRX traded down $1.19 during midday trading on Friday, reaching $23.10. The stock had a trading volume of 692,277 shares, compared to its average volume of 941,670. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company's fifty day simple moving average is $24.88 and its two-hundred day simple moving average is $20.34. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -11.38 and a beta of 0.70. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67.
About Pacira BioSciences
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Further Reading
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
